A Comparison of Erectile Dysfunction Improvement Between Patients With Regular Hemodialysis and Patients With Continuous Ambulatory Peritoneal Dialysis.

BACKGROUND: Erectile dysfunction (ED) is one of the sexual dysfunctions that are often encountered as a complication of male patients with stage 5 chronic kidney disease (stage 5 CKD). ED can be caused by psychological factors in patients with regular dialysis therapy. Currently, Hemodialysis (HD) therapy is the first choice in dialysis therapy and only 2% of stage 5 CKD patients are using Continuous Ambulatory Peritoneal Dialysis (CAPD) as a dialysis therapy. ED in stage 5 CKD patients should become a part of the treatment of patients with dialysis, which hopefully will improve the quality of life of patients. This study aims to compare the improvement in ED degree in patients with HD and CAPD. METHOD: This study is an observational analytic comparative study involving 44 male patients with stage 5 CKD; 22 of whom underwent HD and the remaining 22 patients underwent CAPD. The differences evaluated were changes in the ED degree before and after dialysis, which were assessed using the International Index of Erectile Function-5 (IIEF-5). RESULT: There were significant differences in the improvement in ED degree and IIEF-5 scores in CAPD group. In the HD group, no significant difference was obtained in the improvement in ED degree and IIEF-5 score. A significant difference was obtained in the improvement in ED degree between the HD and CAPD groups by comparing the improvement in IIEF-5 score. CONCLUSION: Patients with CAPD have a better improvement in ED degree than patients with HD. Duarsa GWK, Kandarini Y, Winarta GK, et al. A Comparison of Erectile Dysfunction Improvement Between Patients With Regular Hemodialysis and Patients With Continuous Ambulatory Peritoneal Dialysis. J Sex Med Rev 2021;18:920-925.

Sexual Dysfunction Reduction in Female Patients with Chronic Kidney Disease Undergoing Continuous Ambulatory Peritoneal Dialysis.

BACKGROUND: chronic kidney disease (CKD) is a major worldwide health problem. One key treatment for end-stage CKD patients is dialysis therapy such as Continuous Ambulatory Peritoneal Dialysis (CAPD). This study aimed to find out the differences in the incidence of sexual dysfunction in women with CKD by CAPD. METHODS: this study was a multicenter observational analytic study design in female samples before CAPD and after CAPD. It was conducted between November 2018 - January 2019 with 26 female respondents. They were assessed using the Female Sexual Function Index (FSFI) questionnaire at pre-CAPD and post-CAPD. RESULTS: the results of the FSFI score before CAPD were 32.77 (SD 19.72) and after CAPD was 48.88 (SD 20.29). Analysis of differences in FSFI scores before and after CAPD demonstrates that there was a significant difference (p = 0.003). CONCLUSION: women with CKD who underwent CAPD, had an increase in FSFI scores compared to before CAPD. Thus, the use of CAPD can be seen to reduce sexual dysfunction and therefore improve the quality of life of women with CKD.

Risk Factors for Prostate Volume Progression After Prostate-Transurethral Resection.

BACKGROUND: Many factors could contribute to the cases of residual benign prostate hypertrophy (BPH) volume after transurethral resection of the prostate (TURP), such as age, obesity, testosterone level, and inflammation. The goal of this study was to determine the risk of tumor necrosis factor-α (TNF-α), transforming growth factor-ß (TGF-ß) in prostate tissue, serum prostate-specific antigen (PSA), serum testosterone, and age in promoting prostate volume progression after TURP. PATIENTS AND METHODS: This was a prospective cohort study on 83 BPH patients who underwent TURP at five hospitals in Bali, Indonesia. Trans-rectal ultrasonography (TRUS) was carried out to examine the prostate's size. Three years after, we redo the TRUS examination to collect the data of the latest prostate size. TNF-α, TGF-ß, serum PSA, testosterone, and age were registered for analysis. We used Pearson's and Spearman's correlation tests and multivariate analytic linear regression test (coefficient ß) by SPSS 13.0 software. RESULTS: Age, testosterone, PSA, TNF-α, TGF-ß were positively correlated to prostate's volume progression. The prostate volume was strongly correlated with age (r= 0.749, p <0.001), PSA level (r=0.896, p <0.001), testosterone level (r=0.818, p <0.001), and TGF-ß (r=0.609, p <0.001). The TNF-α level has a weak correlation to prostate's volume progression (r=0.392, p <0.001). CONCLUSION: TNF-α, TGF-ß, PSA, testosterone, and age were significant as the risk factors in promoting the prostate volume progression after TURP.